Results 91 to 100 of about 29,580 (292)

A Proteomics Resource Investigating Fibrosis: Proof‐of‐Concept for Identifying Novel Drug Candidates

PROTEOMICS, EarlyView.
ABSTRACT Fibrosis is characterised by inappropriate wound healing and the buildup of excessive fibrous connective tissue, in particular within the extracellular matrix (ECM). This can occur in multiple organs, ultimately leading to organ failure. Despite the high burden of fibrosis, treatment options only delay disease progression.
Hanne Devos, Manousos Makridakis, Rafael Stroggilos, Mayra Alejandra Jaimes Campos, Aggeliki Tserga, Marika Mokou, Maria G. Roubelakis, Jerome Zoidakis, Antonia Vlahou, Agnieszka Latosinska   +9 more
wiley   +1 more source

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing [PDF]

, 2013
Ruxolitinib, an oral JAK1 and JAK2 inhibitor, is approved in the US for patients with intermediate or high-risk myelofibrosis (MF), a chronic neoplasm associated with aberrant myeloproliferation, progressive bone marrow fibrosis, splenomegaly, and ...
Jorge Cortes, Ruben A Mesa
core   +1 more source

Integrated multi‐omics analysis reveals metabolic reprogramming as a key driver of angiotensin II‐induced vascular remodeling

VIEW, EarlyView.
This study investigates the molecular alterations underlying angiotensin II (Ang II)‐induced vascular remodeling in cardiovascular diseases using a multi‐omics approach. Through data exploration and integrated multi‐omics analysis, our findings reveal that Ang II‐driven vascular injury in vascular smooth muscle cells is mediated by metabolic ...
Yiwei Hu, Dan Zhao, Lingyan Zhong, Jianxujie Zheng, Dongxue Zhang, Enhui Wu, Qian Shi, Liang Qiao, Ling Lin   +8 more
wiley   +1 more source

BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. [PDF]

, 2013
Small molecule inhibition of the BET family of proteins, which bind acetylated lysines within histones, has been shown to have a marked therapeutic benefit in pre-clinical models of mixed lineage leukemia (MLL) fusion protein-driven leukemias.
Bannister, AJ, Barbieri, I, Calero-Nieto, FJ, Cannizzaro, E, Dawson, MA, Godfrey, A, Gottgens, B, Green, AR, Huntly, B, Kouzarides, T, Li, J, Nangalia, J, Prinjha, RK, Rioja, I, Robson, S, Wiese, M, Wyspiańska, BS   +16 more
core   +1 more source

Pathogenesis of Vitiligo: Integrating Immune and Non‐Immune Cell Crosstalk

The Journal of Dermatology, EarlyView.
ABSTRACT Vitiligo is an acquired autoimmune disease characterized by depigmented macules resulting from melanocyte loss. It is a complex multifactorial disorder in which genetic predisposition is combined with environmental factors; however, its detailed etiology remains unclear.
Shintaro Inoue
wiley   +1 more source

Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic [PDF]

, 2017
Reduction-oxidation factor 1-apurinic/apyrimidinic endonuclease (Ref-1/APE1) is a critical node in tumor cells, both as a redox regulator of transcription factor activation and as part of the DNA damage response.
Fehrenbacher, Jill C., Fishel, Melissa L., Kelley, Mark R., Logsdon, Derek, Messmann, Richard A., Shah, Fenil   +5 more
core   +1 more source

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Haematologica, 2016
RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera.
Srdan Verstovsek, Alessandro M. Vannucchi, Martin Griesshammer, Tamas Masszi, Simon Durrant, Francesco Passamonti, Claire N. Harrison, Fabrizio Pane, Pierre Zachee, Keita Kirito, Carlos Besses, Masayuki Hino, Beatriz Moiraghi, Carole B. Miller, Mario Cazzola, Vittorio Rosti, Igor Blau, Ruben Mesa, Mark M. Jones, Huiling Zhen, Jingjin Li, Nathalie Francillard, Dany Habr, Jean-Jacques Kiladjian   +23 more
doaj   +1 more source

Ruxolitinib for Myelofibrosis [PDF]

New England Journal of Medicine, 2012
Steffen, Koschmieder, Adriane, Koppelle, Hans, Seifert   +2 more
openaire   +4 more sources

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

British Journal of Haematology, EarlyView.
Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan, Imran Omerdeen, Bethan Psaila   +2 more
wiley   +1 more source

CO96 Subgroup Analysis of Quality of Life and Treatment Satisfaction By Baseline Patient Characteristics: Pooled Results from Two Randomized Phase 3 Studies of Ruxolitinib Cream for the Treatment of Vitiligo [PDF]

, 2022
AG Pandya, Nanja van Geel, Kathleen Butler, Kristen Bibeau, Jessy Gao, Khaled Ezzedine   +5 more
openalex   +1 more source